Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune, systemic inflammatory disorder that primarily affects diarthrodial joints (1) . To date, various genome-wide association studies have identified over 100 risk loci for RA (2, 3) . One gene found to be highly associated with RA is PTPN2, which encodes for the protein tyrosine phosphatase (PTP) PTPN2, also known as T cell PTP (2) . PTPN2 also strongly associates with inflammatory bowel disease (4) . Homozygous carriage of the risk allele at the rs1893217 SNP -which tags an autoimmunity-associated PTPN2 haplotyperesults in a 33%-50% decrease in PTPN2 mRNA in human CD4 + memory T cells (5) . Also, the same rs1893217 risk allele drove reduced PTPN2 protein expression and acted as a loss-of-function variant when transfected into THP-1 cells (6) .
PTPN2 is a ubiquitously expressed PTP, and in hematopoietic cells it works as an important negative regulator of T cell receptor (TCR) and cytokine signaling by dephosphorylating the SRC-family kinases Lck and Fyn, Janus kinase-1 (JAK1) and JAK3, and signal transducer and activator of transcription-1 (STAT1), STAT3, and STAT5 (7) (8) (9) (10) (11) .
How loss of function of PTPN2 promotes risk of RA and other autoimmune diseases is incompletely understood. However, the importance of PTPN2 in inflammation is exemplified by the fact that global deletion of Ptpn2 in mice leads to early lethality due to progressive systemic myeloid cell-driven inflammation (12) . Further experiments with mice carrying conditional deletion of Ptpn2 demonstrated that PTPN2 also plays a critical role in maintenance of T cell tolerance. Mice carrying T cell-specific deletion of Ptpn2 showed enhanced TCR signaling, altered thymic selection, and increased proliferation of peripheral T cells, together resulting in CD8-driven systemic autoimmunity (9) . Complete Ptpn2 deficiency in T cells also favored CD4 polarization toward a Th1 and Th17 fate, promoting aggressive colitis (13) , which correlated with increased Th1 and Th17 marker expression in inflamed colon tissue from Crohn's disease patient carriers of rs1893217 (13) .
Although these studies point to a role of PTPN2 in modulation of T cell tolerance, it remains unclear how loss of function of PTPN2 affects autoimmunity-protective FoxP3 + regulatory T cells (Tregs) (14, 15) . Two studies showing that complete knockout (KO) (9, 10) of Ptpn2 promotes Treg expansion and FoxP3 stabilization in induced Tregs (16) suggest that loss of function of Ptpn2 in Tregs might partially counterbalance the autoimmunity Genetic variants at the PTPN2 locus, which encodes the tyrosine phosphatase PTPN2, cause reduced gene expression and are linked to rheumatoid arthritis (RA) and other autoimmune diseases. PTPN2 inhibits signaling through the T cell and cytokine receptors, and loss of PTPN2 promotes T cell expansion and CD4-and CD8-driven autoimmunity. However, it remains unknown whether loss of PTPN2 in FoxP3 + regulatory T cells (Tregs) plays a role in autoimmunity. Here we aimed to model human autoimmune-predisposing PTPN2 variants, the presence of which results in a partial loss of PTPN2 expression, in mouse models of RA. We identified that reduced expression of Ptpn2 enhanced the severity of autoimmune arthritis in the T cell-dependent SKG mouse model and demonstrated that this phenotype was mediated through a Treg-intrinsic mechanism. Mechanistically, we found that through dephosphorylation of STAT3, PTPN2 inhibits IL-6-driven pathogenic loss of FoxP3 after Tregs have acquired RORγt expression, at a stage when chromatin accessibility for STAT3-targeted IL-17-associated transcription factors is maximized. We conclude that PTPN2 promotes FoxP3 stability in mouse RORγt + Tregs and that loss of function of PTPN2 in Tregs contributes to the association between PTPN2 and autoimmunity.
expression of Ptpn2 to levels comparable to what was reported for carriers of disease-associated PTPN2 SNPs (Supplemental Figure  1F ), enhances severity of arthritis in a T cell-mediated but not in an innate immune cell-mediated model of arthritis.
Ptpn2 haploinsufficiency promotes enrichment of Th17 cells and ectopic lymphoid-like structures. Next, we immunophenotyped

Ptpn2
+/+ and Ptpn2 +/-SKG mice subjected to mannan-induced arthritis. We found no difference in the number of total CD4 + T cells or in effector populations Th1 and Th17 or Tregs in popliteal lymph nodes of Ptpn2 +/+ versus Ptpn2 +/-SKG mice ( Figure 3A ). In SKG arthritic ankles we mainly found CD4 + T cells with an effector phenotype ( Figure 3B ), while, consistent with previous reports, CD8 + T cells were almost absent (24, 25) . Arthritic joints from Ptpn2 +/-SKG mice displayed increased numbers of CD4 + T cells (Figure 3 , F and G). The formation of these lymphoid nodules was reminiscent of the ectopic lymphoid structures (ELSs) that are present within the synovium of a subgroup of RA patients and correlate with more severe disease course (26) . Th17 cells can contribute to the formation of ELS through production of IL-17, which stimulates expression of CXCL13 (26, 27) . Consistent with the increased accumulation of Th17 cells in Ptpn2 +/-SKG arthritic ankles, we found an increased expression of ELS-associated genes including Cxcl12, Cxcl13, Lta, Ltb, and Prdm1 (28) in the same joints ( Figure 3H ), while there was no difference in the expression of Bcl6. Together, these results further support the notion that increased arthritis in Ptpn2 +/-SKG mice is mediated through a Th17-dependent mechanism.
T cell-specific haploinsufficiency of Ptpn2 promotes arthritis. Previous studies have concluded that B cells play a minor role, if any, in SKG arthritis (24) . Accordingly, B cell depletion during the arthritic phase did not influence disease severity in SKG mice (Supplemental Figure 2) ; thus it is unlikely that promotion of SKG arthritis by Ptpn2 haploinsufficiency is mediated through an action on B cells.
We therefore turned our attention to T cells. To verify that the partial loss of function of Ptpn2 promotes SKG arthritis through a T cell-intrinsic mechanism, we generated SKG mice carrying T cell-specific haploinsufficiency of Ptpn2 on the B6 background. First, we backcrossed the SKG mutation onto the B6 background for 10 generations. mice showed enrichment of Th17 cells in popliteal lymph nodes and arthritic ankles similar to that seen in SKG mice ( Figure 4C ). risk induced by Ptpn2 KO in FoxP3 -CD4 + and CD8 + T cells. However, the role of PTPN2 or other tyrosine phosphatases in Tregs has yet to be addressed through cell-specific genetic manipulation.
In the present study, aimed to model the effect of partial loss of function of PTPN2 in autoimmunity-prone human carriers, we assessed whether haploinsufficiency of Ptpn2 enhances severity of disease in multiple models of RA. We show that Ptpn2 haploinsufficiency promotes CD4-driven autoimmune arthritis. Unexpectedly, we found that partial loss of function of Ptpn2 in Tregs promotes autoimmunity by destabilizing FoxP3 expression in the context of arthritis-induced inflammation. Figure 1 , A-C, shows an in silico assessment of the extent of overlap between RA-associated SNPs and DNase I hypersensitivity sites (DHSs) and active histone marks in the PTPN2 locus for different immune cell types. This type of analysis is useful for insight about the key cellular players where the PTPN2 locus selectively harbors a higher number of cis-regulatory DNA elements (DHSs) and which are thus most likely to be perturbed by the RA-associated SNPs (17) . We found that the PTPN2 locus shows distinct patterns of DHS and histone modifications in CD4 + T cells as compared with B cells and monocytes ( Figure 1A and Supplemental Figure 1A and Supplemental Table 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI123267DS1), suggesting that the locus is more accessible and active in T cells. CD4 + memory T cells were particularly enriched for DHS within the PTPN2 locus (Figure 1B  and Supplemental Table 2 ). RA-associated PTPN2 SNPs that directly overlap with DHSs were also enriched in CD4 + T cells, overall pointing to CD4 + T cells as the key cellular target of PTPN2-dependent pathogenesis of RA ( Figure 1C and Supplemental Table 3 ).
Results
PTPN2 haploinsufficiency promotes T cell-mediated arthritis.
Since PTPN2 regulates important functions in innate immune cells such as macrophages and in synovial fibroblasts (7, 18) , we first subjected Ptpn2 +/+ and Ptpn2 +/-BALB/c mice to K/BxN passive serum transfer and collagen antibody-induced arthritis (CAIA), 2 models dependent on innate immune cells (19) (20) (21) (22) . In these models, Ptpn2 haploinsufficiency did not affect development of arthritis ( Figure 1D and Supplemental Figure 1 , B and C), suggesting that partial loss of function of Ptpn2 does not enhance the arthritogenic action of innate immune cells.
We next evaluated the effect of Ptpn2 haploinsufficiency in the SKG model of autoimmune arthritis. The Zap70 SKG (W163C) mutation results in altered thymic selection and emergence of self-reactive T cells that, in the context of the H-2 d haplotype, result in Th17 cell-dependent spontaneous arthritis (23, 24) . Partial loss of function of Ptpn2 significantly increased spontaneous development of arthritis in female SKG mice ( Figure 1E ), with increased cartilage depletion and bone damage (Supplemental Figure 1, D and E) .
Arthritis onset can be synchronized in SKG mice by injection of mannan (23) . Male Ptpn2 +/-SKG mice developed worse arthritis after injection of mannan, correlating with significantly increased expression of the inflammatory cytokines Il1b, Tnf, Il6, Tnfsf11 (the gene encoding RANK ligand), and Il17a in arthritic ankles (Figure 2, A-D) . We also observed an increased severity of mannaninduced arthritis in female Ptpn2 +/-SKG mice (data not shown). We conclude that Ptpn2 haploinsufficiency, which reduces the Figure 5D ). These data confirm that Ptpn2 haploinsufficiency enhances arthritis through an action on CD4 + T cells. Compiled data from at least 2 independent experiments are shown in D and E. Arthritis severity was quantified using the area under the curve. Bars represent mean ± SEM. **P < 0.01, ***P < 0.001 by Mann-Whitney.
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leads to increased expansion of SKG CD4 + T cells and their effector subsets after transfer into lymphopenic hosts.
Thymic selection and TCR signaling are not altered by Ptpn2 haploinsufficiency. Complete deletion of Ptpn2 in T cells alters thymic selection and promotes peripheral expansion of specific T cell clones, effects that depend on the role of PTPN2 as a negative regulator of TCR signaling (9, 10, 29) . However, we did not find any evidence for altered thymic selection or selective expansion of specific peripheral Vβ CD4 + T cell clones in Ptpn2 +/-SKG mice compared with Ptpn2 +/+ SKG mice (Supplemental Figure 3 , B and C). Also, we did not detect any differences in the induction of CD69 or CD25 after TCR stimulation between Ptpn2 +/+ and Ptpn2 +/-naive SKG CD4 + T cells (Supplemental Figure 4, A and B) .
In order to understand how Ptpn2 haploinsufficiency affects CD4 + T cell differentiation during SKG arthritis, we generated CD4 + T cell chimeras by transferring CD4 + T cells isolated from prearthritic CD45.1 and CD45.2 Ptpn2 +/+ or Ptpn2 +/-SKG mice into Rag2-KO mice ( Figure 5E ). Assessment of arthritic chimeric mice revealed preferential expansion of Ptpn2 +/-SKG CD4 + T cells over Ptpn2 +/+ SKG CD4 + T cells in lymph nodes ( Figure 5F ). We observed preferential expansion of Ptpn2 +/-SKG Tregs in the spleen and of Th1 and especially Th17 cells in lymph nodes (Figure 5, G and H) . The above-mentioned phenotype was not due to differences in the frequencies of naive or effector subsets of CD4 + T cells in the prearthritic mice used for adoptive transfer (Supplemental Figure 3A) . We conclude that Ptpn2 haploinsufficiency Figure 4C ). This enhanced sensitivity to IL-2 correlated with significantly increased differentiation into Th1 cells from naive Ptpn2 +/-SKG CD4 + T cells, while there was no evidence of enhanced IFN-γ signaling (Supplemental Figure 4 , D and E). However, IFN-γ-producing SKG CD4 + T cells, i.e., Th1 cells, play a protective role in SKG arthritis (31) . Accordingly, global KO of IFN-γ aggravated arthritis development in SKG mice (SupAlthough further studies are needed to conclusively rule out a role for Ptpn2 haploinsufficiency in thymic selection, our data strongly suggest that Ptpn2 haploinsufficiency promotes arthritis development through peripheral expansion of pathogenic Th17 and perhaps also Th1 cells.
Increased sensitivity to IL-2 in Ptpn2-haploinsufficient CD4 + T cells. Although an expansion of Ptpn2
+/-Th1 cells was only observed in T cell-chimeric mice and not in arthritic Ptpn2 +/-SKG mice, we did consider a potential arthritogenic role of Ptpn2-haploinsufficient Th1 cells. Since IL-2 promotes differentiation of Th1 cells (30) and previous reports have identified PTPN2 as an important plemental Figure 4F ). We conclude that although increased IL-2 signaling in Ptpn2 +/-SKG mice can promote Th1 (and potentially Treg) expansion, Th1 cells are unlikely to mediate the increased arthritis severity observed in these mice.
Enhanced arthritis is driven by IL-6 and IL-17. Development of arthritis in SKG mice is partially dependent on IL-6 and IL-17 (23, 25, 31) . We verified the IL-17-dependence of SKG arthritis and lymphoid nodule development by treating SKG and SKG CD4 + T cell-recipient Rag2-KO mice with IL-17A-neutralizing antibodies during the course of mannan-induced arthritis (Supplemental and Ptpn2 +/-SKG mice with IL-17A-neutralizing or IL-6 receptorblocking (IL-6R-blocking) antibodies. Both treatments eliminated differences in arthritis development and lymphocyte accumulation in arthritic ankles between Ptpn2 +/+ and Ptpn2 +/-SKG mice ( Figure 6 , A-C), while only partially suppressing disease development. Another cytokine that is important for the pathogenesis of arthritis in SKG mice is TNF-α (25). However, we did not find any difference in TNF-α production between Ptpn2 +/+ and Ptpn2 Figure 5E ). These data suggest that the increased arthritis in Ptpn2 +/-SKG mice is driven by IL-6 and IL-17 but not by increased TNF-α production from CD4 + T cells. We only detected minimal IL-6 production from SKG CD4 + T cells, which was unaffected by Ptpn2 haploinsufficiency (Supplemental Figure 5 , F and G), pointing to T cell-extrinsic sources of IL-6 as critical for the enhanced arthritis of Ptpn2 +/-SKG mice. PTPN2 haploinsufficiency promotes conversion of Tregs. IL-6 is required for the differentiation of naive CD4 + T cells into Th17 (32) . In contrast to previous reports showing that complete loss of Ptpn2 promotes Th17 differentiation (13) , naive SKG CD4 + T cells from Ptpn2 +/-mice did not display enhanced capacity for Th17 differentiation in vitro ( Figure 6D ). This was not due to an altered expression of the il6r complex in Ptpn2 +/-naive SKG CD4 + Lck-Cre + (female, n = 8; male, n = 9) mice. Compiled data from at least 2 independent experiments are presented. Arthritis severity was quantified using the area under the curve. Bars represent mean ± SEM. **P < 0.01, ***P < 0.001 by Mann-Whitney. T cells (Supplemental Figure 5H) . Thus, the accumulation of Th17 observed in arthritic joints of Ptpn2 +/-SKG mice is unlikely to be due to increased differentiation of naive CD4 + T cells into Th17. IL-6-dependent conversion of FoxP3 + Tregs into IL-17-producing FoxP3 -T cells has previously been reported in the collagen-induced arthritis (CIA) model, and suggested as a source of autoreactive IL-17-producing cells in RA (33) . We therefore questioned whether Ptpn2 haploinsufficiency promotes IL-6-dependent loss of FoxP3 by Tregs and transdifferentiation into IL-17-producing T cells in SKG mice. Figure 6E shows -T cells to Rag2-KO mice and subjecting recipient mice to mannan-induced arthritis (Supplemental Figure 5 , I and J). We found that during arthritis, Ptpn2-haploinsufficient Tregs displayed significantly increased conversion into FoxP3 -IL-17A-producing cells (exTregs; Figure  6F ). These data point to a role of PTPN2 as a regulator of Treg stability during autoimmune inflammation. T cells (F; n = 6) and effector populations Th1 and Th17 in lymph nodes (H; n = 6) and Tregs in the spleen (G; n = 4) of T cell chimeras during the arthritic phase (12-14 weeks after transfer) in Rag2-KO mice. Compiled data from at least 2 independent experiments are presented. Each symbol in C-H represents an individual mouse. Arthritis severity was quantified using the area under the curve. Bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by Mann-Whitney (A and C) or paired t test (F-H). Figure 6C) . We identified around 1820 differentially expressed genes (DEGs; fold change > 2, adjusted P value < 0.05) between Tregs and exTregs ( Figure 8A ). Several Th17-associated genes (e.g., Il17a, Rorc, Il22, Il23r) were found to be upregulated in exTregs, whereas several ; Figure 7A ) carry Treg-specific haploinsufficiency of Ptpn2, in which YFP identifies cells currently expressing FoxP3 (Tregs), whereas tdTomato marks cells that are expressing (Tregs) or did express FoxP3 (exTregs). When subjected to mannan-induced arthritis, we found that female mice carrying Treg-specific haploinsufficiency of Ptpn2 displayed enhanced arthritis severity ( Figure 7B ). Ptpn2-haploinsufficient Tregs did not display reduced suppressive functions (Supplemental Figure 6 , A and B), consistent with previous data from complete-KO Tregs (9) . Instead, increased arthritis in mice carrying Treg-specific Ptpn2 haploinsufficiency correlated with increased frequencies of IL-17-producing exTregs in both joint-draining lymph nodes and arthritic ankles ( Figure 7C +/+ (n = 7) and Ptpn2 +/-(n = 9) SKG Tregs were analyzed in lymph nodes of arthritic mice. Compiled data from at least 2 independent experiments are shown. Each symbol in D-F represents an individual mouse. Arthritis severity was quantified using the area under the curve. Bars represent mean ± SEM. *P < 0.05, **P < 0.01 by Mann-Whitney (A and C) or unpaired t test (E and F). Figure 7A ). Gene expression clustering revealed separated genetic expression profiles between Tregs and in vitro-generated exTregs ( Figure 9A ). We identified around 870 DEGs (fold change > 2, adjusted P value < 0.05) between Tregs and in vitro-generated exTregs (Supplemental Figure 7B) . Although in vitro generation of exTregs resulted in a reduced number of DEGs in comparison with in vivo exTregs, in vitro-generated exTregs showed highly similar enrichment in Th17-associated genes (e.g., Il17, Rorc, and Tnfsf11) and reduced expression of Treg-associated genes (e.g., Foxp3 and Ctla4) ( Figure 9, A and B) . When we compared the expression of 30 genes that have been reported to define the Th17 and Treg transcriptional programs (15, (33) (34) (35) (36) , we found very high similarity between exTregs isolated from fate-mapping mice and in vitro-generated exTregs ( Figure 9C and Supplemental Figure 7 , Treg-associated genes (e.g., Foxp3, Ctla4, Grzmb, Gpr83) were downregulated in exTregs ( Figure 8A ). Gene expression clustering (fold difference > 2, adjusted P value < 0.05) confirmed highly differential transcriptional patterns between exTregs and Tregs, indicating that exTregs represent a unique population that has lost its Treg identity (Figure 8 , B and C). IL-17 + exTregs also expressed several genes important for homing to synovial tissue and RA pathogenesis, e.g., Cxcr6, Ccr6, Ccl20, and Tnfsf11 (Figure 8, A-C Figure 8D ), suggesting that PTPN2 is an upstream regulator of pathways that control Treg stability rather than skewing specific transcriptional patterns in exTregs.
In vitro-generated exTregs recapitulate in vivo exTregs. We next sought to assess whether the exTregs generated in our in vitro conversion assay displayed sufficient similarities to the exTregs found in vivo to enable mechanistic studies of the role of PTPN2 in Treg Compared with Tregs, exTregs showed an almost complete lack of accessible chromatin pattern at the Foxp3 loci, which was similar to that seen in sorted Th17 cells ( Figure 10H ). Evaluation C and D). The similarity in gene expression profile between in vitro and in vivo exTregs was further supported by pathway analysis, which showed almost identical pathway enrichment between the 2 populations (Supplemental Figure 7E) . Furthermore, as seen in vivo, there was no difference in gene expression profiles between in vitro-generated Ptpn2 +/+ and Ptpn2 +/-exTregs (Supplemental Figure 7F) . We conclude that in vitro IL-6-induced exTregs do display high phenotypic similarity to exTregs found in vivo in arthritic SKG mice. The residual difference between the transcriptomes of in vitro IL-6-induced and in vivo exTregs suggests that additional stimuli are needed to fully recapitulate in vitro either the population heterogeneity or the transcriptional program of in vivo exTregs.
exTregs display a unique chromatin landscape. Next, we assessed whether the generation of exTregs was also associated with changes in chromatin accessibility. SKG Tregs were stimulated with IL-6 in vitro and isolated after 24 hours (Tregs 24h), 48 hours (Tregs 48h), and 72 hours (Tregs 72h) of culture, and their chromatin accessi- Next, we sorted effector and resting Tregs from Ptpn2 +/+ and Ptpn2 +/-FoxP3 eGFP SKG mice and subjected them to in vitro conversion (Supplemental Figure 8B) . We further confirmed that Rorc was primarily expressed in effector Tregs by quantitative PCR and flow cytometry (Supplemental Figure 8 , B-D; expression of Prdm1 was used to confirm sorting of effector Tregs). There was no difference in expression of Foxp3 between sorted effector and resting Tregs (Supplemental Figure 8C) ; however, effector Tregs showed enhanced tendency to lose FoxP3 and convert into IL-17 + exTregs despite lower expression of IL-6 receptors ( Figure 11 , B-D, and Supplemental Figure 8E ). As shown in Figure 11 , B-D, Ptpn2 haploinsufficiency (which resulted in 50% reduction of Ptpn2 expression; Supplemental Figure 8F ) selectively enhanced the in vitro conversion of effector but not resting Tregs into exTregs. This was not associated with decreased expression of CD25 in effector Tregs -which reportedly correlates with enhanced Treg to exTreg conversion (33) -or with differences in expression of RORγt between Ptpn2 +/+ and Ptpn2 +/-resting or effector Tregs (Supplemental Figure  8 , A, G, and H). These data suggest that IL-17-producing exTregs are generated via loss of FoxP3 by effector RORγt + Tregs and that Ptpn2 selectively promotes FoxP3 stability in effector RORγt + Tregs but not IL-6-induced expression of RORγt in Tregs.
Ptpn2 haploinsufficiency promotes IL-6-induced FoxP3 instability in effector RORγt
+ Tregs. To further evaluate the mechanism by which IL-6 promotes conversion of Tregs into exTregs, we treated Ptpn2 +/+ and Ptpn2 +/-resting Tregs, which have low expression or no expression of RORγt, with ruxolitinib, an inhibitor of the JAK1-2/STAT3 pathway downstream of the IL-6 receptor (39, 40). of the Rorc loci showed gradually increasing chromatin accessibility during Treg dedifferentiation, and Tregs and exTregs after 72 hours displayed a pattern similar to that seen in Th17 cells ( Figure  10I ). However, in contrast to the Rorc loci, only exTregs showed a pattern of increased chromatin accessibility similar to that seen in Th17 cells in the extended Il17a and Il17f loci ( Figure 10J ).
Together these results suggest that during IL-6-driven dedifferentiation, Tregs undergo specific changes in chromatin accessibility that include a progressive opening of the Rorc loci. On the other hand, exTregs display a unique chromatin landscape compared with Tregs at other stages, characterized, among other changes, by the closure of the Foxp3 loci and increased chromatin accessibility of the Il17 loci, conducive to active Il17 transcription. Furthermore, the concentration of newly opened loci at 48 hours of stimulation suggests that key molecular mechanisms of Treg destabilization occur at this stage.
Ptpn2 regulates stability of RORγt + effector Tregs. Consistent with the above-mentioned chromatin accessibility assessment, analysis of in vitro SKG exTreg generation showed that IL-6-driven conversion into FoxP3 -exTregs occurs via upregulation of RORγt in Tregs followed by subsequent loss of FoxP3 from RORγt + Tregs and expression of IL-17 in RORγt + FoxP3 -exTregs ( Figure 11A ). RORγt + Tregs have been described in vivo as having an effector phenotype (37, 38) . In line with previous reports, RORγt + SKG Tregs displayed an effector phenotype with high expression of CD44 and low expression of CD62L and also showed high expression of ICOS and CCR6 similar to that seen in Th17 cells (Supplemental Figure 8A) . Figure 8I ). However, neither ruxolitinib nor Ptpn2 haploinsufficiency affected IL-6-induced upregulation of RORγt in resting Tregs ( Figure 11, E and F) . These data provide evidence that Treg to exTreg conversion is promoted by IL-6-induced activation of the JAK/STAT pathway, although further studies in vivo -e.g., for bZIP-family TFs and decreased accessibility for ETS-family TFs was observed in converted exTregs 72h, which in addition also displayed enrichment of motifs for Runt-family TFs. On the contrary, nonconverted Tregs 72h displayed an opposite profile characterized by enrichment of ETS-family TF motifs and ble at consecutive stages of IL-6-induced Treg dedifferentiation. We found that in the first 48 hours there was an enrichment of motifs for TFs belonging to the bZIP family, whereas accessibility of binding motifs for the ETS-family TFs was reduced. After an additional 24 hours the same trend toward increased accessibility 
FoxP3
-exTregs (top right, dot plot and histograms), and loss of FoxP3 within the RORγt + population (bottom dot plot and histograms). Compiled data from 2 experiments are presented (C-F). Each symbol represents an individual mouse. Bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by unpaired t test (C and D) or 2-way ANOVA (F).
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In further support that STAT3 is a target for PTPN2 in Tregs, we could coimmunoprecipitate PTPN2 and STAT3 from lysates of in vitro-expanded Tregs ( Figure 13A ). To confirm a direct functional interaction between PTPN2 and STAT3, we performed in vitro dephosphorylation and substrate trapping experiments. In support of a direct role of PTPN2 in regulation of STAT3 activation, we found that PTPN2 dephosphorylates STAT3 pY705 (Figure 13B) . Furthermore, we found that a substrate trapping mutant of PTPN2 (D182A, Q260A) could form a physical complex with phosphorylated STAT3 (pTyr705) but not with unphosphorylated STAT3 (Figure 13C) .
Together, these results suggest a model ( Figure 13D ) where PTPN2 selectively inhibits JAK/STAT-dependent loss of FoxP3 in IL-6-stimulated RORγt + effector Tregs -at a stage when chromatin accessibility for Tregs destabilizing TFs is maximized -which in turn inhibits RORγt-dependent IL-17 production. IL-6-induced upregulation of RORγt in Tregs does not promote loss of FoxP3 and, surprisingly, appears to occur through a JAK-and PTPN2-independent pathway.
Discussion
In this study we aimed to clarify the functional genetics of PTPN2 in autoimmunity by focusing on mouse models of RA carrying semideletion of Ptpn2, which reduces the expression of Ptpn2 in immune cells to a level comparable to what has been reported in human carriers of PTPN2 haplotypes associated with RA and inflammatory bowel disease. Global deletion of Ptpn2 in BALB/c mice results in spontaneous subchondral bone erosion and synovitis; however, no further experimental investigation of the role of PTPN2 in RA has been reported (46) . Although Ptpn2 haploinsufficiency does not trigger spontaneous autoimmunity in B6 mice reduction in bZIP-family TF motifs ( Figure 12A ). Several members of the bZIP transcription factor family (such as BATF, JunB, and Fosl2) have been associated with the Th17 differentiation program (35, 41) , whereas members of the ETS family (such as ETS-1) have been associated with stabilization and functions of Tregs (42, 43) . Among members of the Runt TF family, Runx1 has an important role in promoting IL-17 production through direct interaction with RORγt (44) .
At no stage of Treg dedifferentiation could we observe differences in chromatin accessibility between Ptpn2 +/+ and Ptpn2 +/-(Supplemental Figure 8L) , suggesting that PTPN2 does not affect Treg dedifferentiation by skewing chromatin accessibility to the above-mentioned TFs. However, although we did not find enrichment of STAT3 binding motifs (but we cannot rule out effects before the time points considered in this study), we noticed that several TFs (indicated by arrows in Figure 12A ) that bind to motifs displaying enhanced accessibility in Tregs 48h (the stage at which the conversion process is maximized) and in exTregs 72h are known in CD4 + T cells to mediate functions of STAT3 (35, 45) . Since STAT3 is a known substrate for PTPN2, we hypothesized that Ptpn2 haploinsufficiency promotes Treg instability via abnormal regulation of STAT3 phosphorylation in RORγt + effector Tregs. Consistent with our hypothesis, we observed an enhanced activation of STAT3 in effector Ptpn2 +/-SKG Tregs after IL-6 stimulation when compared with Ptpn2 +/+ SKG Tregs ( Figure 12B ). To confirm that PTPN2 regulates Treg conversion through an action on STAT3, we sorted Tregs from .Stat3 fl/+ (PTPN2-KO STAT3-het) B6 mice. PTPN2-KO Tregs showed enhanced susceptibility to conversion into exTregs, which was abrogated by semi-loss of STAT3 ( Figure 12C and Supplemental Figure 8M ). T cells, Ptpn2-haploinsufficient naive CD4 + T cells did not show increased IL-6-driven differentiation into Th17. This could be due to differences between WT and SKG naive T cells or between IL-6 and IL-2 signaling amplification in Ptpn2 -/-versus Ptpn2 +/-T cells. Here we suggest that loss of FoxP3 by RORγt + Tregs significantly contributes to the increased numbers of IL-17-producing cells observed in Ptpn2 +/-arthritic mice. We show that Treg-specific haploinsufficiency of Ptpn2 is sufficient to enhance severity of arthritis in SKG mice and replicates the phenotype seen in mice carrying haploinsufficiency of Ptpn2 in all T cells. We did not find any defect of suppressive function of Ptpn2-haploinsufficient Tregs, consistent with previous data in mice carrying complete deletion of Ptpn2 (9). However, Ptpn2-haploinsufficient RORγt + Tregs are more sensitive to IL-6-dependent loss of FoxP3 and conversion into IL-17A-producing exTregs that can transfer arthritis to Rag2-KO recipient mice. Since no conditional deletion of Ptpn2 or of other tyrosine phosphatases in Tregs has been reported to date and the role of Ptpn2 in Tregs in the context of inflammation has not been explored yet, our results also highlight for the first time a potential role of a tyrosine phosphatase in Treg stability in the context of autoimmune inflammation.
Since it has been reported that complete loss of Ptpn2 causes expansion of Tregs and enhances FoxP3 stability in inducible Tregs (9, 16), we were surprised to find that Ptpn2 haploinsufficiency promotes autoimmunity through destabilization of Tregs. Also the enhanced in vitro IL-2 signaling observed in Ptpn2-haploinsufficient naive CD4 + T cells and the potentially IL-2 signalingdependent expansion of disease-protective Th1 cells and Tregs in lymphopenic animals might sound inconsistent with the proposed arthritogenic role of Ptpn2 haploinsufficiency in SKG mice. However, in arthritic Ptpn2
+/-SKG mice we could not detect any expan- (9), we show that it is able to enhance incidence and severity of disease on an autoimmune-prone background. This exemplifies the importance of modeling human autoimmune-associated variants in an autoimmunity-prone context, reflecting the additional risk factors that are needed in humans to trigger disease. Our data point to haploinsufficiency of Ptpn2 being able to sustain some but not all of the immunological functions reported for Ptpn2 (9) (10) (11) 29) . For example, while complete deletion or deep knockdown of Ptpn2 revealed a major role of this enzyme in limiting myeloid cell-and synoviocyte-driven inflammation (7, 18) , we find that innate immune cells are not critical mediators of the pathogenic action of Ptpn2 haploinsufficiency. We show here that Ptpn2 haploinsufficiency in autoreactive T cells promotes expansion of Th1, Treg, and pathogenic Th17 cells under lymphopenic conditions. Complete deletion of Ptpn2 is known to promote lymphopenic expansion of naive CD4 + and CD8 + T cells through enhancement of TCR signaling, while IL-7 signaling was unaffected (29) . However, we did not find significant evidence of increased TCR signaling in Ptpn2-haploinsufficient SKG mice. Similarly, conditional haploinsufficiency of Ptpn2 in T cells on the B6 background did not result in increased TCR sensitivity or altered thymic selection (9) . On the other hand, the enhanced IL-2 signaling found in Ptpn2-haploinsufficient T cells is reminiscent of the phenotype of Ptpn2 -/-T cells, which display increased IL-2-mediated Treg expansion (9, 47) . Thus, we speculate that enhanced IL-2 signaling underlies the observed expansion of Ptpn2-haploinsufficient Th1 cells and Tregs in lymphopenic conditions. Ptpn2 haploinsufficiency also led to marked expansion of pathogenic IL-17-producing CD4 + T cells after transfer of SKG CD4 + T cells into lymphopenic hosts. However, in contrast to previous reports on naive Ptpn2 -/- Arthritis models. For the K/BxN serum transfer model, arthritis was induced in 8-week-old male BALB/c mice by i.p. injection of serum obtained from arthritic K/BxN mice. Every 2 days, development of arthritis was assessed by measurement of ankle thickness using a digital caliper according to an established protocol (53) .
For the SKG mouse model, both spontaneous and mannaninduced arthritis were assessed. For mannan-induced arthritis, male and female mice were injected i.p. with 20 mg of mannan (Sigma-Aldrich), dissolved in sterile PBS at 8 weeks of age. Clinical scoring and measurement of ankle thickness using a digital caliper was performed twice weekly according to an established protocol (24) . Briefly, clinical signs of arthritis in front and hind paws were scored as follows: 0, no joint swelling; 0.1 per swollen finger joint (3 digits on front paw and 4 digits on hind paw); 0.5, mild swelling of wrist or ankle; 1.0, severe swelling of wrist or ankle. Scores for all finger joints of forepaws and hind paws, wrists, and ankles were combined for each mouse, yielding a maximum score of 5.4, which was considered the clinical endpoint. Mice reaching clinical endpoint scores were sacrificed according to ethical guidelines.
For neutralization of IL-17, female and male SKG mice or Rag2-KO mice were injected with 100 μg of anti-IL-17 antibody (clone 17F3, Bio X Cell) both retro-orbitally and i.p. 1-2 hours before injection of mannan, after which mice received anti-IL-17 antibody once weekly (100 μg) by i.p. injection. For neutralization of IL-6 signaling, male SKG mice received weekly i.p. injections of 200 μg anti-IL-6R (clone 15A7, Bio X Cell) antibody, with the first injection performed 2 hours before injection of mannan. Antibody-treated mice were compared with control untreated mice.
All arthritis studies were performed on littermate mice. For treatment experiments, mice with the same genotype were randomly selected for treatment with cytokine-neutralizing or control. Clinical scoring of mice was performed in a blinded manner in which genotypes and treatments were unknown to the researcher during scoring. (48) and in CIA (33) . However, the molecular mechanism of FoxP3 loss in Tregs has remained unexplored. Here we show that during IL-6-driven dedifferentiation, Tregs undergo specific changes in chromatin accessibility. In this context, enhanced IL-6-dependent loss of FoxP3 in Ptpn2-haploinsufficient Tregs correlates with enhanced phosphorylation of STAT3, and depends on JAK activity and STAT3 expression. Importantly, T cell phenotyping and chromatin analysis shows that loss of Ptpn2 selectively destabilizes effector Tregs and suggests that STAT3 phosphorylation in Tregs is only able to modulate FoxP3 stability in RORγt + Tregs, without affecting IL-6-dependent RORγt expression. Thus, our data also suggest potential differences in signaling pathways mediating IL-6-dependent RORγt induction and in downstream STAT3-dependent signaling between Tregs and FoxP3 -T cells. In conclusion, reduced Ptpn2 expression promotes arthritis through enhanced IL-6 signaling in effector Tregs, causing increased STAT3 phosphorylation that renders RORγt + Tregs more susceptible to loss of FoxP3. It remains to be established whether the arthritogenic effect of Ptpn2 haploinsufficiency is exerted on natural Tregs and/or peripherally induced Tregs. Also, the importance of PTPN2 as a regulator of JAK/STAT signaling suggests that further studies are warranted on the potential role of Ptpn2 haploinsufficiency in enhancing signaling of additional JAK/STAT activator cytokines that might play a role in the pathogenesis of SKG arthritis (e.g., IL-23 and IL-10).
CD4 + T cell transfer and generation of T cell chimeras in
Our study shows the importance of considering gene dosage when performing functional genetics studies and sheds light on unexpected functions of tyrosine phosphatases and the potential uniqueness of signaling pathways involved in Treg stability. Further studies of tyrosine phosphatases in resting versus effector Tregs and of the molecular program underlying STAT3-dependent loss of FoxP3 in effector Tregs hold the promise of unraveling novel mechanisms of tolerance and autoimmunity.
Methods
Mice. SKG mice have already been described (23 Figure 7G) . Additional information regarding experimental methods can be found in Supplemental Methods.
Data availability. RNA-Seq and ATAC-Seq data discussed in this publication have been deposited in the NCBI's Gene Expression Omnibus (GEO) database and are accessible through GEO Series accession number GSE123488.
Statistics. Sample sizes were selected based on our experience with the above-mentioned assays in order to achieve sufficient power to detect biologically relevant differences in the experiments being conducted with an α error (2-tailed) less than 0.05.
For statistical analysis, 2-tailed Mann-Whitney U test was performed on nonparametric data. On normally distributed data, 2-tailed paired t test or 2-tailed unpaired t test was performed as reported in the figure legends. For comparison of multiple parameters, 2-way ANOVA was used. All statistical analyses were performed using GraphPad Prism software. A comparison was considered significant if P was less than 0.05.
Study approval. The studies in animals were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the LJI (protocol AP140-NB4) and the IACUC of UCSD (protocol S16098), and in accordance with the National Health and Medical Research Council Australian Code of Practice for the Care and Use of Animals under approval of the Peter MacCallum Animal Ethics and Experimentation Committee (Ethics number AEEC 570, 604).
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MNDS and NB conceived of, designed, and supervised the research, analyzed data, and wrote the paper. MNDS, KMD, BJS, DJW, CS, WBK, BP, SB, FW, RG, GS, ES, and SY contributed to acquisition and analysis of data. IA, GK, PM, SS, MK, MLT, PV, TT, and FA provided tools and/or reagents and key scientific input. All authors approved the final version of the paper. lated with Dynabeads mouse anti-CD3/CD28 T cell activation beads (Invitrogen) with or without addition of IL-6 (BioLegend; 50 ng/ml) for 24-72 hours. At the end of stimulation, cells were restimulated with PMA (20 ng/ml), ionomycin (1 μM), and brefeldin A for 5 hours and analyzed for the expression of IL-17A, FoxP3, and RORγt using flow cytometry. Ruxolitinib (Selleck Chemical) was used for inhibition of JAK1/2 signaling, and the inverse agonist GSK805 (EMD Millipore Calbiochem) was used for inhibition of RORγt function.
For conversion assay using Ptpn2 sorted by flow cytometry and stimulated with plate-bound anti-CD3 (10 μg/ml) and soluble anti-CD28 (5 μg/ml) for 72 hours in the presence of IL-6 (50 ng/ml). After 72 hours, cells were stimulated in the presence of ionomycin (1 μg/ml), PMA (20 ng/ml), and BD Golgi-Plug (BD Biosciences) and analyzed for the expression of IL-17A, RORγt, and FoxP3 using flow cytometry. Further information regarding antibodies used for flow cytometry staining can be found in Supplemental Methods.
In Figure 7A ) using the IL-17 Secretion kit as described above.
